NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCATS E-041-2021-2-US-01 RALDH1 Inhibitors For The Immunotherapy Of Hepatocellular Carcinoma US 63/351,624 Abandoned
NIAID E-153-2019-1-US-13 Recombinant Prefusion Measles And Mumps F And F-HN Glycoproteins And Their Use US National Stage 17/784,605 Pending
NCI E-123-2020-0-US-01 FIRST SARS-COV-2 VACCINE IMMUNOGENS US 63/351,196 Expired
NCI E-148-2021-0-PCT-02 COMPOSITIONS AND METHODS FOR DETERMINING RESPONSIVENESS TO IMMUNE CHECKPOINT INHIBITORS (ICI), INCREASING EFFECTIVENESS OF ICI, AND TREATING CANCER PCT PCT PCT/US2022/032917 Expired
NCI E-106-2021-0-PCT-02 COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME PCT PCT PCT/US2022/032798 Expired
NCI E-003-2020-0-US-08 PERSONALIZED TUMOR VACCINE AND USE THEREOF FOR CANCER IMMUNOTHERAPY US National Stage 17/783,866 Pending
NCATS E-156-2022-0-US-01 COMPOUNDS FOR INHIBITING GRAM-POSITIVE BACTERIA US 63/350,533 Expired
NLM E-111-2022-0-US-01 REAL-TIME ARTIFICIAL INTELLIGENCE FOR OPEN-WORLD AND EXPLAINABLE ECHOCARDIOGRAPHY ANALYSIS AND QUANTIFICATION US 63/350,720 Expired
NCI E-234-2014-1-JP-02 METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF JP DIV 2022-092616 Issued
NHLBI E-025-2019-0-US-03 ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF US National Stage 17/783,345 Pending
NCI E-121-2022-0-US-01 COMPOSITIONS, SYSTEMS, AND METHODS FOR DELIVERY OF THERAPEUTICS US 63/350,315 Expired
NCI E-028-2015-1-HK-43 Anti-Mutated Kras T Cell Receptors HK CN 42022054674.1 Issued
NCI E-021-2015-0-JP-37 Anti-CD70 Chimeric Antigen Receptors JP DIV 2022-092594 Issued
NCI E-145-2019-0-US-07 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF US National Stage 17/783,171 Pending
NIDDK E-160-2022-0-US-01 COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY US 63/349,626 Expired
NCI E-186-2022-0-US-01 PREDICTING PATIENT RESPONSE TO CANCER THERAPY VIA HISTOPATHOLOGY IMAGES US 63/349,829 Expired
NIAID E-153-2019-1-IL-07 MUMPS AND MEASLES VIRUS IMMUNOGENS AND THEIR USE IL National Stage 293666 Pending
NCI E-118-2021-0-PCT-02 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors PCT PCT PCT/US2022/032378 Expired
NCI E-055-2011-0-US-13 BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USE US DIV 17/833,383 Pending
NCATS E-006-2022-0-US-01 LATS INHIBITORS AND USES THEREOF US 63/349,337 Expired
NHLBI E-025-2019-0-CA-05 ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF CA National Stage 3160855 Abandoned
NIAID E-193-2021-0-US-01 CELL-PENETRATING ANTIMICROBIAL AGENT US 63/365,841 Expired
NIAID E-080-2013-0-US-09 ATTENUATION OF HUMAN RESPIRATORY SYNCYTIAL VIRUS BY GENOME SCALE CODON-PAIR DEOPTIMIZATION US CON 17/831,259 12054749 Issued PDF
NHLBI E-045-2020-0-US-04 Cyclooxygenase-2 Inhibition For The Treatment Of SAA-high Asthma US National Stage 17/781,530 Abandoned
NCI E-133-2016-0-JP-11 FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS USING SAME JP DIV 2022-089863 Abandoned
NIAID E-093-2022-0-US-01 COMPOSITIONS AND METHODS FOR DETECTING LYMPHATIC FILARIASIS US 63/347,794 Expired
NCI E-031-2021-0-PCT-02 NITROXIDE RADICALS AS ANTIVIRAL TREATMENT FOR CORONAVIRUS INFECTION PCT PCT PCT/US2022/031405 Expired
NHLBI E-085-2019-0-HK-06 METHODS FOR ASSESSING CARDIOVASCULAR DISEASE OR INFLAMMATORY DISEASE RISK USING NON-EXCHANGEABLE LIPID PROBE HK EP 62022054258.8 Pending
NHLBI E-186-2014-1-US-17 SUPERAGONISTS, PARTIAL AGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 US CON 17/825,660 12202873 Issued PDF
NEI E-155-2020-0-PCT-01 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS PCT PCT COMB PCT/US2022/031136 Expired
NEI E-153-2020-0-PCT-02 Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells PCT PCT PCT/US2022/031107 Expired
NCI E-044-2020-0-US-03 METHODS OF IDENTIFYING CELL-TYPE-SPECIFIC GENE EXPRESSION LEVELS BY DE-CONVOLVING BULK GENE EXPRESSION US National Stage 17/780,356 Pending
NIDDK E-112-2021-0-PCT-02 Vitamin C Renal Leak As A Clinical Diagnostic Tool In The Detection, Monitoring And Management Of Acute And Chronic Diseases PCT PCT PCT/US2022/030935 Expired
NEI E-114-2023-0-US-01 OPHTHALMIC FORMULATION CAPABLE OF DELIVERING METFORMIN TO CHOROID RPE AND RETINA US 63/345,759 Expired
NCI E-149-2015-0-AU-07 Methods of Isolating T Cells and T Cell Receptors Having Antigen Specificity for a Cancer-Specific Mutation from Peripheral Blood AU DIV 2022203507 Issued
NIAID E-103-2020-0-US-04 Broadly Neutralizing and Potent Antibodies Against HIV US National Stage 17/778,536 Pending
NCI E-230-2012-0-EP-70 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 EP DIV 22 174 521.9 Pending
NCI E-151-2019-0-JP-01 TASPASE1 INHIBITORS AND USES THEREOF JP National Stage 2022-529821 Abandoned
NCI E-151-2019-0-CA-01 TASPASE1 INHIBITORS AND USES THEREOF CA National Stage 3162244 Pending
NIAID E-103-2022-0-US-01 Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus US 63/365,015 Expired
NCATS E-128-2019-0-US-07 SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME US National Stage 17/777,654 12552737 Issued PDF
NCI E-151-2019-0-US-02 TASPASE1 INHIBITORS AND USES THEREOF US National Stage 17/777,971 Pending
NCI E-205-2010-1-US-04 PHOTOSENSITIZING ANTIBODY-FLUOROPHORE CONJUGATES US CON 17/746,740 12296013 Issued PDF
NCI E-023-2019-0-US-05 INHIBITORS OF HISTONE DEMETHYLASES (PFI-63 AND PFI-90) FOR THE TREATMENT OF CANCER AND FOR THE INHIBITION OF HISTONE DEMETHYLASE IN CELLS US National Stage 17/777,552 Pending
NCI E-172-2022-0-US-01 Method Of Subtyping Of Small Cell Lung Cancer Using Plasma Cell-Free Nucleosomes US 63/342,763 Expired
NCI E-040-2012-0-US-65 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen US CON 17/745,067 12180484 Issued PDF
NCI E-023-2019-0-CA-03 INHIBITORS OF HISTONE DEMETHYLASES (PFI-63 AND PFI-90) FOR THE TREATMENT OF CANCER AND FOR THE INHIBITION OF HISTONE DEMETHYLASE IN CELLS CA National Stage 3158557 Pending
NCI E-209-2014-0-JP-20 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO JP DIV 2022-079474 Issued
NCI E-094-2022-0-US-01 PIM-TARGETED PROTACS AND METHODS OF USE US 63/341,757 Expired
NIAAA E-087-2021-0-PCT-02 A FACILE AND ODOR-FREE APPROACH TO CONVERT SULFONYL UREA DERIVATIVES TO CHALCOGENIDE SULFONYL UREA DERIVATIVES PCT PCT PCT/US2022/028942 Expired